SynthesisThe American journal of gastroenterology2023
Patients With Crohn's Disease and Permanent Ileostomy Are Universally Excluded From Clinical Trials: A Systematic Review.
Synthesis in The American journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel Disease.Inflammatory bowel diseases · 2024Pooled it
- Management of complications in patients with an ileostomy: an umbrella review of systematic reviews for the EndOTrial Consortium.International journal of colorectal disease · 2024Pooled it
- Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohn's Disease in the Biologic Era: An Updated Systematic Review with Meta-analysis.Journal of Crohn's & colitis · 2024Pooled it
- Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease.Crohn's & colitis 360 · 2026Article
- Gaining the Upper Hand - Upadacitinib for Crohn's Disease with Ileostomy: A Real-World Gap Addressed.Digestive diseases and sciences · 2026Article
- Endoscopic Recurrence in Crohn's Disease Patients With Long-Term Ileostomy.Inflammatory bowel diseases · 2025Article
- Patients with Crohn's Disease and Ileostomy Can Respond to Upadacitinib.Digestive diseases and sciences · 2025Article
- Editorial: Striking the Right Balance for Eligibility Criteria for Clinical Trials in Inflammatory Bowel Disease.United European gastroenterology journal · 2025Article
- Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2024Review
- Interventions for Adjunctive Care in Patients With Inflammatory Bowel Disease and Permanent Ileostomy: A Systematic Review.Crohn's & colitis 360 · 2024Article
- Navigating the complexities of drug development for inflammatory bowel disease.Nature reviews. Drug discovery · 2024Review
- Toward Patient Centricity: Why Do Patients With Inflammatory Bowel Disease Participate in Pharmaceutical Clinical Trials? A Mixed-Methods Exploration of Study Participants.Crohn's & colitis 360 · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
introductionWe performed a systematic review to investigate whether patients with Crohn's disease (CD) and permanent ileostomy (PI) have been included in clinical trials evaluating biologics and small molecules.
methodsMEDLINE, Embase and Cochrane library (CENTRAL) data bases were searched from inception to May 16, 2022 for placebo controlled induction and/or maintenance randomized controlled trials assessing biologics and oral small molecules in adult patients with active CD.
resultsOf the 81 induction and maintenance trials assessing biologics and oral small molecules in CD, none permitted the enrollment of patients with PI. Patients with CD and PI have been universally excluded from pharmaceutical trials of biologics and small molecules to date. DISCUSSION: There is an urgent need to identify barriers to enrollment and develop eligibility and outcome measures enabling the inclusion of patients with CD and PI into clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.